JP2014534196A5 - - Google Patents

Download PDF

Info

Publication number
JP2014534196A5
JP2014534196A5 JP2014535789A JP2014535789A JP2014534196A5 JP 2014534196 A5 JP2014534196 A5 JP 2014534196A5 JP 2014535789 A JP2014535789 A JP 2014535789A JP 2014535789 A JP2014535789 A JP 2014535789A JP 2014534196 A5 JP2014534196 A5 JP 2014534196A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
rasagiline
weight
amount
propargyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014535789A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014534196A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/059356 external-priority patent/WO2013055687A2/en
Publication of JP2014534196A publication Critical patent/JP2014534196A/ja
Publication of JP2014534196A5 publication Critical patent/JP2014534196A5/ja
Pending legal-status Critical Current

Links

JP2014535789A 2011-10-10 2012-10-09 Ｒ（＋）−ｎ−ホルミル−プロパルギル−アミノインダン Pending JP2014534196A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161545422P 2011-10-10 2011-10-10
US61/545,422 2011-10-10
PCT/US2012/059356 WO2013055687A2 (en) 2011-10-10 2012-10-09 R(+)-n-formyl-propargyl-aminoindan

Publications (2)

Publication Number Publication Date
JP2014534196A JP2014534196A (ja) 2014-12-18
JP2014534196A5 true JP2014534196A5 (https=) 2015-12-03

Family

ID=48042235

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014535789A Pending JP2014534196A (ja) 2011-10-10 2012-10-09 Ｒ（＋）−ｎ−ホルミル−プロパルギル−アミノインダン

Country Status (15)

Country Link
US (1) US9346746B2 (https=)
EP (1) EP2766002A4 (https=)
JP (1) JP2014534196A (https=)
KR (1) KR20140090996A (https=)
CN (1) CN103874487A (https=)
AR (1) AR088297A1 (https=)
AU (1) AU2012323349A1 (https=)
BR (1) BR112014008555A2 (https=)
CA (1) CA2851276A1 (https=)
EA (1) EA201490761A1 (https=)
HK (1) HK1200315A1 (https=)
IL (1) IL231721A0 (https=)
MX (1) MX2014004308A (https=)
WO (1) WO2013055687A2 (https=)
ZA (1) ZA201403043B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2551481T3 (es) * 2006-02-21 2015-11-19 Teva Pharmaceutical Industries, Ltd. Uso de rasagilina para el tratamiento de atrofia multisistémica
JP5769923B2 (ja) * 2006-04-03 2015-08-26 テバ ファーマシューティカル インダストリーズ リミティド レストレスレッグス症候群の治療のためのラサギリンの使用
CN101557706B (zh) * 2006-12-14 2013-08-07 泰华制药工业有限公司 雷沙吉兰碱结晶固体
EP2234478A4 (en) * 2008-01-11 2013-01-23 Teva Pharma RASAGILINE FORMULATIONS, THEIR PREPARATION AND USE
WO2009151594A1 (en) * 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
SI2451771T1 (sl) 2009-07-09 2014-10-30 Ratiopharm Gmbh Soli rasagilina in njihovi farmacevtski pripravki
AU2010304755A1 (en) * 2009-10-09 2012-05-24 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Progressive Supranuclear Palsy
EP2515891A4 (en) * 2009-12-22 2013-06-05 Teva Pharma 3-keto-N-propargyl-1-aminoindan
JP2013537530A (ja) 2010-07-27 2013-10-03 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトレートの分散物
JP2014534197A (ja) 2011-10-10 2014-12-18 テバ ファーマシューティカル インダストリーズ リミティド Ｒ（＋）−ｎ−メチル−プロパルギルアミノインダン
JP2015529196A (ja) 2012-08-17 2015-10-05 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンの非経口製剤

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3201470A (en) * 1965-08-17 Chsx c cech
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
US5877218A (en) * 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
EP0738149B1 (en) * 1994-01-10 2006-11-29 Teva Pharmaceutical Industries, Ltd. 1-aminoindan derivatives and compositions thereof
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
ES2241064T3 (es) 1996-12-18 2005-10-16 Teva Pharmaceutical Industries, Ltd. Derivados de aminoindano.
JP2003512426A (ja) * 1999-10-27 2003-04-02 テバ ファーマシューティカル インダストリーズ リミティド 双極性気分障害における躁病の治療のための１−アミノインダンの使用。
ES2432117T3 (es) 2002-11-15 2013-11-29 Teva Pharmaceutical Industries Limited Uso de rasagilina con riluzol para tratar la esclerosis lateral amiotrófica
WO2004072250A2 (en) 2003-02-06 2004-08-26 University Of Georgia Research Foundation, Inc. Galacturonosyl transferases, nucleic acids encoding same and uses therefor
WO2006014973A2 (en) 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
US20090111892A1 (en) 2004-11-24 2009-04-30 Shulamit Patashnik Rasagiline Orally Disintegrating Compositions
WO2006091657A1 (en) 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
CA2630037C (en) 2005-11-17 2015-03-31 Teva Pharmaceutical Industries Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
ES2551481T3 (es) 2006-02-21 2015-11-19 Teva Pharmaceutical Industries, Ltd. Uso de rasagilina para el tratamiento de atrofia multisistémica
JP5769923B2 (ja) 2006-04-03 2015-08-26 テバ ファーマシューティカル インダストリーズ リミティド レストレスレッグス症候群の治療のためのラサギリンの使用
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
CN101557706B (zh) 2006-12-14 2013-08-07 泰华制药工业有限公司 雷沙吉兰碱结晶固体
CN101600346B (zh) 2006-12-14 2013-08-21 泰华制药工业有限公司 雷沙吉兰的单宁酸盐
EP1987816A1 (de) 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
CA2698695A1 (en) 2007-09-05 2009-03-12 Teva Pharmaceutical Industries Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
EP2234478A4 (en) 2008-01-11 2013-01-23 Teva Pharma RASAGILINE FORMULATIONS, THEIR PREPARATION AND USE
WO2009151594A1 (en) 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
MX2010013766A (es) 2008-06-13 2011-03-15 Teva Pharmaceutical Ind Ltd Star Rasagilina para modificacion de enfermedad de parkinson.
BRPI0909997A2 (pt) 2008-06-19 2015-10-27 Teva Pharma r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino
US8334409B2 (en) 2008-06-19 2012-12-18 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
DE102008064061A1 (de) 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189791A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
SI2451771T1 (sl) 2009-07-09 2014-10-30 Ratiopharm Gmbh Soli rasagilina in njihovi farmacevtski pripravki
AU2010304755A1 (en) 2009-10-09 2012-05-24 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Progressive Supranuclear Palsy
CN102048717B (zh) * 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
EP2515891A4 (en) * 2009-12-22 2013-06-05 Teva Pharma 3-keto-N-propargyl-1-aminoindan
AU2011282720B2 (en) 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
JP2013537530A (ja) 2010-07-27 2013-10-03 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトレートの分散物
SG189454A1 (en) 2010-10-26 2013-05-31 Teva Pharma Deuterium enriched rasagiline
AU2012323346A1 (en) 2011-10-10 2014-05-15 Teva Pharmaceutical Industries Ltd Rasagiline citramide
JP2014534197A (ja) 2011-10-10 2014-12-18 テバ ファーマシューティカル インダストリーズ リミティド Ｒ（＋）−ｎ−メチル−プロパルギルアミノインダン
JP2015529196A (ja) 2012-08-17 2015-10-05 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンの非経口製剤

Similar Documents

Publication Publication Date Title
JP2014534196A5 (https=)
JP2014534197A5 (https=)
JP7266298B2 (ja) プリドピジンの調節放出製剤
JP2012512907A5 (https=)
CN104334169B (zh) 包含氨基羧酸盐的固体组合物
CN102114011B (zh) 一种布洛芬缓释制剂及其制备方法
CN101322695B (zh) 双氯芬酸钾缓释胶囊及其生产工艺
CN103585122B (zh) 一种含依维莫司的片剂及其制备方法
CN104758265A (zh) 一种雷诺嗪缓释片药物组合物及其制备方法
KR20150092385A (ko) 솔리페나신을 포함하는 안정한 제제 및 이의 제조방법
CN104800183B (zh) 一种阿司匹林肠溶片及其制备方法和应用
CN106943367B (zh) 一种马来酸阿法替尼片及其制备方法
WO2018230504A1 (ja) 顆粒剤、並びに錠剤及びその製造方法
CN104706606B (zh) 一种枸橼酸西地那非片剂及其制备方法
CN106478598B (zh) 一种凡德他尼水合物晶体及其制备方法
CN103142533B (zh) 一种依托泊苷肠溶片
CN106943368A (zh) 米氮平片剂及其制备方法
CN101032484A (zh) 一种噻托溴铵胶囊型吸入粉雾剂
JPWO2017064814A1 (ja) ジエノゲスト含有錠剤
EP2531180A2 (en) Oral complex composition comprising pseudoephedrine and levocetirizine
CN103735520B (zh) 一种间苯三酚颗粒剂及其制备方法
Chaturvedi et al. Comparative Evaluation of Natural and Semi-Synthetic Superdisintegrants in the formulation of Oro-dispersible Tablets of Norfloxacin
CN110038013A (zh) 一种头孢呋辛酯固体制剂及其制备工艺
CN105769807B (zh) 一种含有非诺贝酸胆碱的药物组合物
CN103142530B (zh) 一种依托泊苷缓释片